Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 4/20 | 0.39 |
| ▸ | CA4 | P22748 | 1/20 | 0.39 |
| ▸ | MME | P08473 | 2/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.38 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | GNPAT | O15228 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL714149 | 1.00 | CA2 (0.39) | CA2CA4MMECA1SLC22A6 | |
| SCHEMBL13253140 | 1.00 | CA2 (0.39) | CA2CA4MMECA1SLC22A6 | |
| SCHEMBL31128440 | 0.83 | ITGB3 (0.46) | GPR84 | |
| SCHEMBL698874 | 0.81 | CA2 (0.40) | CA2CA4MMECA1TDP1 | |
| SCHEMBL715097 | 0.81 | CA2 (0.40) | CA2CA4MMECA1TDP1 | |
| SCHEMBL698875 | 0.81 | CA2 (0.40) | CA2CA4MMECA1TDP1 | |
| SCHEMBL8080233 | 0.79 | ITGB3 (0.36) | CA2SMN1; SMN2 | |
| SCHEMBL8980517 | 0.78 | CA2 (0.41) | CA2CA4MMECA1SLC22A6 | |
| SCHEMBL27523949 | 0.78 | CA2 (0.41) | CA2CA4MMECA1SLC22A6 | |
| SCHEMBL20335027 | 0.78 | ALDH1A1 (0.52) | CA2MMECA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117355337-A | Protein-macromolecule conjugates and methods of use thereof | 奥迪曼药业科技有限公司 | 2024-01-05 | — | — | CN | disclosed |
| US-8586638-B2 | Parakeratosis inhibitor and skin preparation for external use | SHISEIDO COMPANY, LTD (JP) | 2013-11-19 | — | — | US | disclosed |
| CN-102274130-B | Application of n- benzene sulfonyl-l-glutamic acid or saline thereof | SHISEIDO CO LTD | 2013-06-12 | — | — | CN | disclosed |
| US-20120253064-A1 | PARAKERATOSIS INHIBITOR AND SKIN PREPARATION FOR EXTERNAL USE | SHISEIDO COMPANY, LTD. (JP) | 2012-10-04 | — | — | US | disclosed |
| EP-2491980-A2 | Parakeratosis inhibitor and skin preparation for external use | SHISEIDO COMPANY LIMITED (JP) | 2012-08-29 | — | — | EP | disclosed |
| EP-2491981-A2 | Parakeratosis inhibitor and external composition for skin | SHISEIDO COMPANY LIMITED (JP) | 2012-08-29 | — | — | EP | disclosed |
| US-20120053243-A1 | PARAKERATOSIS INHIBITOR AND SKIN PREPARATION FOR EXTERNAL USE | SHISEIDO COMPANY, LTD. (JP) | 2012-03-01 | — | — | US | disclosed |
| CN-102274130-A | Application of n- benzene sulfonyl-l-glutamic acid or saline thereof | — | 2011-12-14 | — | — | CN | disclosed |
| CN-102266269-A | Parakeratosis inhibitor and external composition for skin | — | 2011-12-07 | — | — | CN | disclosed |
| CN-1886114-B | Parakeratosis inhibitor and composition for external use on skin | SHISEIDO CO LTD | 2011-08-10 | — | — | CN | disclosed |
| US-20070225380-A1 | Parakeratosis Inhibitor and Skin Preparation for External use | SHISEIDO COMPANY LTD. (JP) | 2007-09-27 | — | — | US | disclosed |
| CN-1886114-A | Parakeratosis inhibitor and composition for external use on skin | SHISEIDO CO LTD (JP) | 2006-12-27 | — | — | CN | disclosed |
| EP-1688126-A1 | PARAKERATOSIS INHIBITOR AND EXTERNAL COMPOSITION FOR SKIN | SHISEIDO COMPANY LIMITED (JP) | 2006-08-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053243-A1 | PARAKERATOSIS INHIBITOR AND SKIN PREPARATION FOR EXTERNAL USE | CUTA, HPN, DNPEP | CA2 2319/4885CA4 2926/4885MME 1500/4885 |
| US-20120253064-A1 | PARAKERATOSIS INHIBITOR AND SKIN PREPARATION FOR EXTERNAL USE | CUTA, HPN, PRSS1 | CA2 2770/4885CA4 3182/4885MME 838/4885 |
| US-20070225380-A1 | Parakeratosis Inhibitor and Skin Preparation for External use | CUTA, HPN, DNPEP | CA2 2319/4885CA4 2926/4885MME 1500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.